Linneah sat at a desk at the Center for Sexual Medicine at Sheppard Pratt in the suburbs of Baltimore and filled out a questionnaire. She read briskly, making swift checks beside her selected answers, and when she was finished, she handed the pages across the desk to Martina Miller, who gave her a round of pills.
The pills were either a placebo or a new drug called Lybrido, created to stoke sexual desire in women. Checking her computer, Miller pointed out gently that Linneah hadn’t been doing her duty as a study participant. Over the past eight weeks, she took the tablets before she planned to have sex, and for every time she put a pill on her tongue, she was supposed to make an entry in her online diary about her level of lust.
“I know, I know,” Linneah said. She is a 44-year-old part-time elementary-school teacher, and that day she wore red pants and a canary yellow scarf. (She asked that only a nickname be used to protect her privacy.) “It’s a mess. I keep forgetting.”
Miller, a study coordinator, began a short interview, typing Linneah’s replies into a database that the medication’s Dutch inventor, Adriaan Tuiten, will present to the Food and Drug Administration this summer or fall as part of his campaign to win the agency’s approval and begin marketing what might become the first female-desire drug in America. “Thinking about your desire now,” Miller said, “would you say it is absent, very low, low, reasonable or present?” SOURCE
